The International Diabetes Federation predicts that by 2035 10% of the population of the
world will have been diagnosed with diabetes, raising serious concerns over the resulting …

Type 2 diabetes mellitus (T2DM) has become a major health problem, threatening the
quality of life of nearly 500 million patients worldwide. As a typical multifactorial metabolic …

Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO)
synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological …

Cardiovascular (CV) complications are an essential causal element of prospect in diabetes
mellitus (DM), with carotid atherosclerosis being a common risk factor for prospective crisis …

Asymmetric dimethylarginine (ADMA) is a competitive endogenous inhibitor of nitric oxide
synthase with a key role in the pathophysiology of endothelial dysfunction, in the …

Background Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and
characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial …

Aims We aimed to determine serum dipeptidyl peptidase-4 (DPP-4) activity in a group of
persons with latent autoimmune diabetes in adults (LADA) and to compare it with persons …

Aims Cardiovascular disease (CVD) is the greatest burden of type 2 diabetes mellitus
(T2DM) in terms of morbility, mortality and costs for individuals and societies. Therefore, its …

Background Accumulating evidence has demonstrated that migration of keratinocytes is
critical to wound epithelialization, and defects of this function result in chronic delayed …

Microvascular complications are the leading causes of acquired blindness, end-stage renal
failure, and varieties of neuropathy associated with diabetes. Asymmetric dimethylarginine …